The announcement of a webcast to provide clinical updates is significant for investors as it may reveal new data or progress in Revolution Medicines' RAS(ON) inhibitor portfolio. Positive updates could lead to increased investor confidence and a potential rise in stock price. The webcast is a direct communication to investors, making it highly relevant.